Revance to Participate in Upcoming Investor Conferences

May 28, 2024

Contacts

Revance Therapeutics, Inc. (NASDAQ:RVNC) today announced that the company will be participating in the following investor conferences.

William Blair 44th Annual Growth Stock Conference


Chief Financial Officer Tobin Schilke is scheduled to present on Tuesday, June 4, 2024, at 11:20 am CT, in Chicago, Illinois.

Goldman Sachs 45th Annual Global Healthcare Conference


President and Chief Executive Officer Mark J. Foley is scheduled to present on Tuesday, June 11, 2024, at 8:00 am ET, in Miami, Florida.

Interested parties can access the live audio webcasts for the conferences from the Investor Relations section of the company’s website at www.revance.com. The webcast replays will be available after the conclusion of the live presentations for approximately 90 days.

About Revance


Revance is a biotechnology company setting the new standard in healthcare with innovative aesthetic and therapeutic offerings that enhance patient outcomes and physician experiences. Revance’s portfolio includes DAXXIFY® (DaxibotulinumtoxinA-lanm) for injection and the RHA® Collection of dermal fillers in the U.S. Revance has also partnered with Viatris Inc. to develop a biosimilar to onabotulinumtoxinA for injection and Shanghai Fosun Pharmaceutical to commercialize DAXXIFY in China.

Revance’s global headquarters and experience center is located in Nashville, Tennessee. Learn more at Revance.com, RevanceAesthetics.com, DAXXIFY.com, HCP.DAXXIFYCervicalDystonia.com, or connect with us on LinkedIn.

“Revance”, the Revance logo, and DAXXIFY are registered trademarks of Revance Therapeutics, Inc. Resilient Hyaluronic Acid® and RHA® are trademarks of TEOXANE SA.

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.